444 related articles for article (PubMed ID: 29102544)
41. Role of oral and gut microbiota in childhood obesity.
Wang W; Yan Y; Yu F; Zhang W; Su S
Folia Microbiol (Praha); 2023 Apr; 68(2):197-206. PubMed ID: 36626083
[TBL] [Abstract][Full Text] [Related]
42. Mind-altering with the gut: Modulation of the gut-brain axis with probiotics.
Kim N; Yun M; Oh YJ; Choi HJ
J Microbiol; 2018 Mar; 56(3):172-182. PubMed ID: 29492874
[TBL] [Abstract][Full Text] [Related]
43. Interaction between gut microbiome and cardiovascular disease.
Peng J; Xiao X; Hu M; Zhang X
Life Sci; 2018 Dec; 214():153-157. PubMed ID: 30385177
[TBL] [Abstract][Full Text] [Related]
44. Gut microbiota and obesity: implications for fecal microbiota transplantation therapy.
Kang Y; Cai Y
Hormones (Athens); 2017 Jul; 16(3):223-234. PubMed ID: 29278509
[TBL] [Abstract][Full Text] [Related]
45. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis.
Tojo R; Suárez A; Clemente MG; de los Reyes-Gavilán CG; Margolles A; Gueimonde M; Ruas-Madiedo P
World J Gastroenterol; 2014 Nov; 20(41):15163-76. PubMed ID: 25386066
[TBL] [Abstract][Full Text] [Related]
46. Bridging the Gap between Gut Microbial Dysbiosis and Cardiovascular Diseases.
Lau K; Srivatsav V; Rizwan A; Nashed A; Liu R; Shen R; Akhtar M
Nutrients; 2017 Aug; 9(8):. PubMed ID: 28796176
[TBL] [Abstract][Full Text] [Related]
47. Autism Spectrum Disorders and the Gut Microbiota.
Fattorusso A; Di Genova L; Dell'Isola GB; Mencaroni E; Esposito S
Nutrients; 2019 Feb; 11(3):. PubMed ID: 30823414
[TBL] [Abstract][Full Text] [Related]
48. Impact of Gut Microbiota Composition on Onset and Progression of Chronic Non-Communicable Diseases.
Noce A; Marrone G; Di Daniele F; Ottaviani E; Wilson Jones G; Bernini R; Romani A; Rovella V
Nutrients; 2019 May; 11(5):. PubMed ID: 31091761
[TBL] [Abstract][Full Text] [Related]
49. Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.
Eom T; Kim YS; Choi CH; Sadowsky MJ; Unno T
J Microbiol; 2018 Mar; 56(3):189-198. PubMed ID: 29492876
[TBL] [Abstract][Full Text] [Related]
50. An overview of microbiome based strategies on anti-obesity.
Chang CS; Ruan JW; Kao CY
Kaohsiung J Med Sci; 2019 Jan; 35(1):7-16. PubMed ID: 30844145
[TBL] [Abstract][Full Text] [Related]
51. The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases.
Sanchez-Rodriguez E; Egea-Zorrilla A; Plaza-Díaz J; Aragón-Vela J; Muñoz-Quezada S; Tercedor-Sánchez L; Abadia-Molina F
Nutrients; 2020 Feb; 12(3):. PubMed ID: 32110880
[TBL] [Abstract][Full Text] [Related]
52. Gut microbiota and probiotics intervention: A potential therapeutic target for management of cardiometabolic disorders and chronic kidney disease?
Cavalcanti Neto MP; Aquino JS; Romão da Silva LF; de Oliveira Silva R; Guimarães KSL; de Oliveira Y; de Souza EL; Magnani M; Vidal H; de Brito Alves JL
Pharmacol Res; 2018 Apr; 130():152-163. PubMed ID: 29410236
[TBL] [Abstract][Full Text] [Related]
53. [Gut microbiota and obesity: Pathogenetic relationships and ways to normalize the intestinal microflora].
Drapkina OM; Korneeva ON
Ter Arkh; 2016; 88(9):135-142. PubMed ID: 28635818
[TBL] [Abstract][Full Text] [Related]
54. Probiotic Ingestion, Obesity, and Metabolic-Related Disorders: Results from NHANES, 1999-2014.
Lau E; Neves JS; Ferreira-Magalhães M; Carvalho D; Freitas P
Nutrients; 2019 Jun; 11(7):. PubMed ID: 31261830
[TBL] [Abstract][Full Text] [Related]
55. The gut microbiome as a target for adjuvant therapy in insomnia disorder.
Kang Y; Kang X; Cai Y
Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101834. PubMed ID: 34800683
[TBL] [Abstract][Full Text] [Related]
56. Diagnostics and therapeutic implications of gut microbiota alterations in cardiometabolic diseases.
Schiattarella GG; Sannino A; Esposito G; Perrino C
Trends Cardiovasc Med; 2019 Apr; 29(3):141-147. PubMed ID: 30126689
[TBL] [Abstract][Full Text] [Related]
57. Gut microbiota in cardiovascular disease and heart failure.
Kitai T; Tang WHW
Clin Sci (Lond); 2018 Jan; 132(1):85-91. PubMed ID: 29326279
[TBL] [Abstract][Full Text] [Related]
58. Gut microbiota and host metabolism in liver cirrhosis.
Usami M; Miyoshi M; Yamashita H
World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
[TBL] [Abstract][Full Text] [Related]
59. Protective Effects of Probiotic Consumption in Cardiovascular Disease in Systemic Lupus Erythematosus.
de la Visitación N; Robles-Vera I; Toral M; Duarte J
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31694260
[TBL] [Abstract][Full Text] [Related]
60. Intestinal dysbiosis and probiotic applications in autoimmune diseases.
de Oliveira GLV; Leite AZ; Higuchi BS; Gonzaga MI; Mariano VS
Immunology; 2017 Sep; 152(1):1-12. PubMed ID: 28556916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
